Byron Nelson
Internal Medicine · Centre, ALNPI 1487673299
Payments from drug & device makers
Across 242 payments — averaging $13.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$633
- AbbVie$467
- AstraZeneca$307
- Novo Nordisk$264
- GSK$206
- Boehringer Ingelheim$197
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,303100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 58 | $633 |
| AbbVie | 36 | $467 |
| AstraZeneca | 18 | $307 |
| Novo Nordisk | 21 | $264 |
| GSK | 16 | $206 |
| Boehringer Ingelheim | 18 | $197 |
| Bayer | 9 | $156 |
| Amgen | 8 | $118 |
| Lilly USA, LLC | 7 | $117 |
| Novartis | 6 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Dexcom, Inc. | 5 | $90 |
| Amarin Pharma, Inc. | 6 | $90 |
| Merck | 5 | $78 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Genentech USA, Inc. | 4 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 2 | $25 |
| Exact Sciences | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Allegis Pharmaceuticals, LLC | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$3,307 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $32,704 |
| JardianceEmpagliflozin | 15 | $12,192 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,247 |
| NamzaricMemantine Hcl/Donepezil Hcl | 26 | $7,491 |
| XareltoRivaroxaban | 16 | $7,139 |
| Pioglitazone-MetforminPioglitazone Hcl/Metformin Hcl | 13 | $1,722 |
| Omeprazole | 145 | $1,351 |
| Levothyroxine Sodium | 145 | $1,062 |
| Tamsulosin Hcl | 143 | $1,048 |
| Levocetirizine Dihydrochloride | 142 | $957 |
| Atorvastatin Calcium | 142 | $956 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $946 |
| Potassium Chloride | 72 | $908 |
| ClopidogrelClopidogrel Bisulfate | 100 | $841 |
| Amlodipine Besylate | 192 | $818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $633 | $32,70468 claims |
| Boehringer IngelheimJardiance | $197 | $12,19215 claims |
| GSKTrelegy Ellipta | $206 | $11,24718 claims |
| AbbVieNamzaric | $467 | $7,49126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Centre
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.